Treatment is diagnosis-specific. Hip OA, GTPS, and inflammatory arthritis are the three most common primary care conditions. Address all modifiable factors simultaneously.
β Hip Osteoarthritis (NICE NG226)
Step 1Education + exercise (mandatory first-line): Physiotherapy referral immediately β aerobic exercise (swimming, cycling) + hip-specific strengthening (abductor strengthening, bridging). Advise: exercise nourishes cartilage and does not accelerate OA. Provide Versus Arthritis OA patient information leaflet
Step 2Analgesia β topical then oral: Topical diclofenac 1% gel over hip TDS (limited evidence for deep joint but reduces systemic NSAID need). Paracetamol 1g QDS regularly if inadequate. Avoid strong opioids (no long-term evidence, significant harm β NICE NG226)
Step 3Oral NSAIDs: Naproxen 250β500 mg BD with food + PPI (omeprazole 20 mg OD if age >65, GI risk, anticoagulated). Lowest effective dose, shortest duration. Check eGFR + BP + CVD risk before starting. Avoid in eGFR <30, heart failure, or uncontrolled hypertension
Step 4Intra-articular corticosteroid injection: Methylprednisolone 80 mg + 0.5% bupivacaine β ultrasound or X-ray guidance essential (deep joint, blind injection inaccurate in ~75% of cases). Short-term benefit 4β12 weeks. Use for flares or pre-physiotherapy to enable exercise participation. Maximum 3β4/year β more frequent use accelerates cartilage loss
Step 5Total hip replacement referral: Oxford Hip Score β€26/48, failed conservative management 3β6 months, significantly impaired QoL. 95% patient satisfaction at 10 years. Discuss: implant lifespan 20β25 years, risks (DVT 1β2%, infection <1%, dislocation 1β3%), realistic recovery (6 weeks to walking, 3 months to full function)
NICE NG226 explicitly states: Do NOT offer opioids for hip OA as regular analgesia. Do NOT offer glucosamine or chondroitin. Do NOT offer arthroscopic lavage. Topical NSAIDs are preferred first pharmacological step over oral.
β‘ Greater Trochanteric Pain Syndrome / Gluteal Tendinopathy
Step 1Load management + education: Avoid provocative positions: crossing legs, sitting with hip >90Β° flexion, lying directly on the affected side (use pillow between knees). Analgesia: paracetamol 1g QDS Β± naproxen 500 mg BD short course. Correct biomechanical contributors (foot pronation, hip abductor weakness)
Step 2Physiotherapy β gluteal tendon loading programme: Progressive hip abductor strengthening (clamshells, side-lying abduction, single-leg stance). Tendon loading is curative β avoid passive stretching of the IT band which compresses the tendon and worsens symptoms. 70% resolve by 12 weeks with supervised programme
Step 3Corticosteroid injection (if >3 months failed conservative): Ultrasound-guided injection into greater trochanteric bursa β methylprednisolone 40 mg + 1% lidocaine. Short-term (3-month) benefit; does not treat underlying tendinopathy. Combine with physiotherapy for sustained effect. Limit to 2β3 lifetime injections
Step 4Failed at 6 months β physiotherapy referral intensification or MSK/orthopaedic review: ESWT (extracorporeal shockwave therapy) β NICE supports use. PRP injection via sports medicine. Surgical trochanteric bursectomy / tendon repair (rare)
β Do NOT perform intra-articular hip injection for GTPS β the pathology is extra-articular. Ultrasound guidance is essential; blind trochanteric injection misses the target in up to 60% of cases.
β’ Polymyalgia Rheumatica (PMR)
Diagnosis
Age >50, bilateral shoulder + hip girdle aching, morning stiffness >45 min, ESR >40 (often >100) + elevated CRP. Exclude: GCA (headache, jaw claudication, visual symptoms β same-day ophthalmology + high-dose prednisolone 40β60 mg). Exclude RA, inflammatory myopathy, malignancy
First-line treatment
Prednisolone 15 mg OD orally β dramatic response within 24β72 hours is both therapeutic and diagnostic. If no response at 1 week, reconsider diagnosis. Add bone protection: alendronate 70 mg weekly + calcium 1000 mg + vitamin D 800 IU daily (steroid-induced osteoporosis prevention β NICE NG187)
Tapering schedule
Reduce to 12.5 mg after 3β4 weeks (if symptoms controlled). Then 10 mg after further 4β6 weeks. Then slow taper: 1 mg reduction every 4β8 weeks. Typical duration: 18β24 months total. Relapse common β increase to last effective dose. Refer rheumatology for relapses or steroid-sparing need (methotrexate, tocilizumab)
Monitoring
ESR/CRP monthly initially. HbA1c + BP + weight (steroid side effects). Annual DEXA on prolonged steroids. Adrenal insufficiency risk if abrupt stop β never stop suddenly
β£ Inflammatory Arthritis β New Presentation
Acute management
Naproxen 500 mg BD + PPI while awaiting rheumatology. Do not initiate DMARD without specialist confirmation. Short course prednisolone (15β20 mg OD Γ 2 weeks) for severe flare while awaiting urgent referral β discuss with rheumatology
Axial SpA / AS
Young male, bilateral SI pain, morning stiffness >60 min, HLA-B27 positive, elevated CRP. Refer rheumatology urgently. NSAIDs are disease-modifying in axial SpA (not just analgesic). MRI SI joints (NICE NG65). Physiotherapy essential β daily extension exercises
Refer urgently
All new inflammatory arthritis β rheumatology within 3 weeks (NICE NG100). Early DMARD (methotrexate Β± hydroxychloroquine for RA) prevents irreversible joint damage. Every week of delay = measurable progression on imaging